ZF2001: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
CSV import |
||
| Line 28: | Line 28: | ||
{{stub}} | {{stub}} | ||
<gallery> | |||
File:ZF2001 logo.webp|ZF2001 | |||
</gallery> | |||
Latest revision as of 01:44, 20 February 2025
ZF2001 is a protein subunit vaccine for COVID-19. It was developed by Anhui Zhifei Longcom Biopharmaceutical, a subsidiary of Chongqing Zhifei Biological Products, and the Institute of Microbiology, Chinese Academy of Sciences.
Etymology[edit]
The name "ZF2001" is derived from the initials of the company that developed it, Zhifei, and the year 2021, when the vaccine was developed.
Development and production[edit]
The ZF2001 vaccine was developed in response to the COVID-19 pandemic. It is a protein subunit vaccine, which means it uses a harmless piece of the virus to trigger an immune response in the body. The vaccine was developed by Anhui Zhifei Longcom Biopharmaceutical and the Institute of Microbiology, Chinese Academy of Sciences.
Efficacy[edit]
Clinical trials have shown that the ZF2001 vaccine has an efficacy rate of 81.76% after three doses. This is comparable to other COVID-19 vaccines currently in use.
Distribution and usage[edit]
As of July 2021, the ZF2001 vaccine has been approved for emergency use in China, Uzbekistan, Indonesia, and Pakistan. It is also under review for emergency use in other countries.
